Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating ...

HepaRegeniX is backed by experienced life science investors, including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, Ascenion ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Enliven Therapeutics, Inc.’s ELVN share price has dipped by 18.28%, which has investors questioning if this is right time to ...

Despite significant advances in Parkinson's disease (PD) treatment, it remains incurable, with limited therapeutic options.

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from ...

Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect ...

Hong Kong restaurant group Masterbeef raised $8M in its IPO earlier this week. Shares of the investment research platform Aether also made ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.00%, which has investors questioning if this is right time to buy.